4 recruiting, 2 not yet recruiting, 1 active not recruiting. 7 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 7 | Recruiting 4, Not yet recruiting 2, Active not recruiting 1 |
Follow Adjuvant Therapy: new trials by email Literature Review of Adjuvant Therapy trials Research Report on Adjuvant Therapy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Prospective, Multicenter, Phase II Clinical Study of Postoperative Chemotherapy Combined With QL1706 for High-risk Triple-negative Breast Cancer. Aipaluoli-tovorilimab plus AC-T chemotherapy as postoperative adjuvant therapy - TNBC, Adjuvant Therapy | Not applicable | Recruiting | The First Affiliated Hospital with Nanjing Medical University | 59 | 2026-06-05 | 2026-06-03 |
| A Single-arm, Multicenter, Phase II Clinical Study of Camrelizumab Combined With Famitinib in Adjuvant Therapy After Radical Resection of Cervical Cancer Camrelizumab, famotinib - Cervical Cancer, Radical Surgery | Not applicable | Not yet recruiting | Jin LI | 30 | 2026-04-01 | 2026-03-12 |
| Pucotenlimab Combined With Chemotherapy as Perioperative Treatment for Locally Advanced Gastroesophageal Junction Carcinoma Neoadjuvant chemo-immunotherapy - Gastroesophageal Junction, Gastric / Gastroesophageal Junction Adenocarcinoma | Not applicable | Not yet recruiting | Tang-Du Hospital | 30 | 2025-08-01 | 2025-07-29 |
| Reduce Sedentary Behavior During Cancer Treatment - the RedSedCan Study Digital self-management program - Breast Cancer, Colorectal Cancer (CRC) | Not applicable | Recruiting | Mälardalen University | 210 | 2025-03-01 | 2026-10-01 |
| MRD in PAAD Adjuvant Therapy Three-drug chemotherapy group, two-drug chemotherapy group - The Role of Molecular Residual Disease in the Treatment Strategy and Prognosis Prediction of Pancreatic Cancer Patients Undergoing Adjuvant Therapy, Molecular Residual Disease | Not applicable | Active not recruiting | Peking Union Medical College Hospital | 60 | 2024-10-15 | 2025-03-10 |
| Postoperative Adjuvant Therapy of Donafenib for Hepatocellular Carcinoma Donafenib - Hepatocellular Carcinoma, Adjuvant Therapy | Not applicable | Recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 204 | 2024-08-28 | 2024-09-03 |
| Irinotecan Liposome Combined With Oxaliplatin and Tegafur as Adjuvant Therapy for Pancreatic Cancer Irinotecan liposome injection - Pancreatic Cancer, Adjuvant Therapy | Not applicable | Recruiting | Kuirong Jiang | 53 | 2024-04-08 | 2024-04-11 |
Pancreatic Neoplasms (2) · Breast Neoplasms (1) · Carcinoma, Hepatocellular (1) · Colorectal Neoplasms (1) · Prostatic Neoplasms (1) · Sedentary Behavior (1) · Uterine Cervical Neoplasms (1)
Neoplasms (5) · Neoplasms by Site (5) · Digestive System Diseases (4) · Digestive System Neoplasms (4) · Endocrine Gland Neoplasms (2) · Endocrine System Diseases (2) · Genital Diseases (2) · Pancreatic Diseases (2) · Urogenital Diseases (2) · Urogenital Neoplasms (2) · Adenocarcinoma (1) · Behavior (1) · Breast Diseases (1) · Carcinoma (1) · Colonic Diseases (1)
Oxaliplatin (1) · Tegafur (1) · camrelizumab (1) · donafenib (1) · irinotecan sucrosofate (1)
Jin LI (1) · Kuirong Jiang (1) · Mälardalen University (1) · Peking Union Medical College Hospital (1) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (1) · Tang-Du Hospital (1) · The First Affiliated Hospital with Nanjing Medical University (1)
China (5) · Sweden (1)
Changzhen Shang, MD (1) · KuiRong Jiang, archiater (1)